Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

264 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
Oliva EN, Alati C, Santini V, Poloni A, Molteni A, Niscola P, Salvi F, Sanpaolo G, Balleari E, Germing U, Fenaux P, Stamatoullas A, Palumbo GA, Salutari P, Impera S, Avanzini P, Cortelezzi A, Liberati AM, Carluccio P, Buccisano F, Voso MT, Mancini S, Kulasekararaj A, Morabito F, Bocchia M, Cufari P, Spiriti MA, Santacaterina I, D'Errigo MG, Bova I, Zini G, Latagliata R. Oliva EN, et al. Among authors: cortelezzi a. Lancet Haematol. 2017 Mar;4(3):e127-e136. doi: 10.1016/S2352-3026(17)30012-1. Epub 2017 Feb 3. Lancet Haematol. 2017. PMID: 28162984 Clinical Trial.
Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy.
Oliva EN, Latagliata R, Laganà C, Breccia M, Galimberti S, Morabito F, Poloni A, Balleari E, Cortelezzi A, Palumbo G, Sanpaolo G, Volpe A, Specchia G, Finelli C, D'Errigo MG, Rodà F, Alati C, Alimena G, Nobile F, Aloe Spiriti MA. Oliva EN, et al. Among authors: cortelezzi a. Leuk Lymphoma. 2013 Nov;54(11):2458-65. doi: 10.3109/10428194.2013.778406. Epub 2013 Mar 27. Leuk Lymphoma. 2013. PMID: 23432724 Clinical Trial.
Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence.
Oliva EN, Lauseker M, Aloe Spiriti MA, Poloni A, Cortelezzi A, Palumbo GA, Balleari E, Sanpaolo G, Volpe A, Ricco A, Ronco F, Alati C, D'Errigo MG, Santacaterina I, Kündgen A, Germing U, Latagliata R. Oliva EN, et al. Among authors: cortelezzi a. Cancer Med. 2015 Dec;4(12):1789-97. doi: 10.1002/cam4.523. Epub 2015 Sep 17. Cancer Med. 2015. PMID: 26376955 Free PMC article.
Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion.
Oliva EN, Cuzzola M, Nobile F, Ronco F, D'Errigo MG, Laganà C, Morabito F, Galimberti S, Cortelezzi A, Aloe Spiriti MA, Specchia G, Poloni A, Breccia M, Ghio R, Finelli C, Iacopino P, Alimena G, Latagliata R. Oliva EN, et al. Among authors: cortelezzi a. Eur J Haematol. 2010 Sep;85(3):231-5. doi: 10.1111/j.1600-0609.2010.01473.x. Epub 2010 May 17. Eur J Haematol. 2010. PMID: 20491881 Clinical Trial.
Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study.
Oliva EN, Cuzzola M, Aloe Spiriti MA, Poloni A, Laganà C, Rigolino C, Morabito F, Galimberti S, Ghio R, Cortelezzi A, Palumbo GA, Sanpaolo G, Finelli C, Ricco A, Volpe A, Rodà F, Breccia M, Alimena G, Nobile F, Latagliata R. Oliva EN, et al. Among authors: cortelezzi a. Ann Hematol. 2013 Jan;92(1):25-32. doi: 10.1007/s00277-012-1569-0. Epub 2012 Sep 16. Ann Hematol. 2013. PMID: 22983750 Clinical Trial.
Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study.
Musto P, Maurillo L, Simeon V, Poloni A, Finelli C, Balleari E, Ricco A, Rivellini F, Cortelezzi A, Tarantini G, Villani O, Mansueto G, Milella MR, Scapicchio D, Marziano G, Breccia M, Niscola P, Sanna A, Clissa C, Voso MT, Fenu S, Venditti A, Santini V, Angelucci E, Levis A. Musto P, et al. Among authors: cortelezzi a. Br J Haematol. 2017 Jun;177(5):741-750. doi: 10.1111/bjh.14621. Epub 2017 Apr 17. Br J Haematol. 2017. PMID: 28419408 Free article.
Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.
Voso MT, Leone G, Piciocchi A, Fianchi L, Santarone S, Candoni A, Criscuolo M, Masciulli A, Cerqui E, Molteni A, Finelli C, Parma M, Poloni A, Carella AM, Spina F, Cortelezzi A, Salvi F, Alessandrino EP, Rambaldi A, Sica S. Voso MT, et al. Among authors: cortelezzi a. Ann Oncol. 2017 Jul 1;28(7):1547-1553. doi: 10.1093/annonc/mdx154. Ann Oncol. 2017. PMID: 28368509 Free article. Clinical Trial.
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes.
Voso MT, Santini V, Finelli C, Musto P, Pogliani E, Angelucci E, Fioritoni G, Alimena G, Maurillo L, Cortelezzi A, Buccisano F, Gobbi M, Borin L, Di Tucci A, Zini G, Petti MC, Martinelli G, Fabiani E, Fazi P, Vignetti M, Piciocchi A, Liso V, Amadori S, Leone G. Voso MT, et al. Among authors: cortelezzi a. Clin Cancer Res. 2009 Aug 1;15(15):5002-7. doi: 10.1158/1078-0432.CCR-09-0494. Epub 2009 Jul 28. Clin Cancer Res. 2009. PMID: 19638460 Free article. Clinical Trial.
Bone Marrow Fibrosis and Early Hematological Response as Predictors of Poor Outcome in Azacitidine Treated High Risk-Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia.
Reda G, Riva M, Fattizzo B, Cassin R, Giannarelli D, Pennisi M, Freyrie A, Cairoli R, Molteni A, Cortelezzi A. Reda G, et al. Among authors: cortelezzi a. Semin Hematol. 2018 Oct;55(4):202-208. doi: 10.1053/j.seminhematol.2018.02.005. Epub 2018 Feb 21. Semin Hematol. 2018. PMID: 30502848 Review.
Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome.
Spiriti MA, Latagliata R, Niscola P, Cortelezzi A, Francesconi M, Ferrari D, Volpe E, Clavio M, Grossi A, Reyes MT, Musto P, Mitra ME, Azzarà A, Pagnini D, D'Arena G, Spadano A, Balleari E, Pecorari P, Capochiani E, De Biasi E, Perego D, Monarca B, Pisani F, Scaramella G, Petti MC. Spiriti MA, et al. Among authors: cortelezzi a. Ann Hematol. 2005 Mar;84(3):167-76. doi: 10.1007/s00277-004-0961-9. Epub 2004 Nov 30. Ann Hematol. 2005. PMID: 15592833 Clinical Trial.
264 results